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Although doxorubicin (DOX) is an effective anti-cancer drug with cytotoxicity in a variety of different 
tumors, its effectiveness in treating glioblastoma multiforme (GBM) is constrained by insufficient 
penetration across the blood–brain barrier (BBB). In this study, biocompatible magnetic iron oxide 
nanoparticles (IONPs) stabilized with trimethoxysilylpropyl-ethylenediamine triacetic acid (EDT) were 
developed as a carrier of DOX for GBM chemotherapy. The DOX-loaded EDT-IONPs (DOX-EDT-IONPs) 
released DOX within 4 days with the capability of an accelerated release in acidic microenvironments. 
The DOX-loaded EDT-IONPs (DOX-EDT-IONPs) demonstrated an efficient uptake in mouse brain-
derived microvessel endothelial, bEnd.3, Madin–Darby canine kidney transfected with multi-drug 
resistant protein 1 (MDCK-MDR1), and human U251 GBM cells. The DOX-EDT-IONPs could augment 
DOX’s uptake in U251 cells by 2.8-fold and significantly inhibited U251 cell proliferation. Moreover, 
the DOX-EDT-IONPs were found to be effective in apoptotic-induced GBM cell death (over 90%) within 
48 h of treatment. Gene expression studies revealed a significant downregulation of TOP II and Ku70, 
crucial enzymes for DNA repair and replication, as well as MiR-155 oncogene, concomitant with 
an upregulation of caspase 3 and tumor suppressors i.e., p53, MEG3 and GAS5, in U251 cells upon 
treatment with DOX-EDT-IONPs. An in vitro MDCK-MDR1-GBM co-culture model was used to assess 
the BBB permeability and anti-tumor activity of the DOX-EDT-IONPs and DOX treatments. While 
DOX-EDT-IONP showed improved permeability of DOX across MDCK-MDR1 monolayers compared to 
DOX alone, cytotoxicity in U251 cells was similar in both treatment groups. Using a cadherin binding 
peptide (ADTC5) to transiently open tight junctions, in combination with an external magnetic field, 
significantly enhanced both DOX-EDT-IONP permeability and cytotoxicity in the MDCK-MDR1-GBM 
co-culture model. Therefore, the combination of magnetic enhanced convective diffusion and the 
cadherin binding peptide for transiently opening the BBB tight junctions are expected to enhance the 
efficacy of GBM chemotherapy using the DOX-EDT-IONPs. In general, the developed approach enables 
the chemotherapeutic to overcome both BBB and multidrug resistance (MDR) glioma cells while 
providing site-specific magnetic targeting.
Glioblastoma multiforme (GBM) is the most common and aggressive form of malignant gliomas whose cur-
rent standard of care involves surgical recession followed by chemotherapy and  radiotherapy1,2. Nevertheless, 
the median survival of GBM patients who receive the current standard of care is 14.6 months post-diagnosis, 
and 5-year survival rate is only 9.8%3. The extensive infiltration of GBM tumors in addition to the presence of 
open
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the blood–brain barrier (BBB) limits chemotherapeutic options. The BBB is made of tight junctions between 
endothelial cells and surrounding astrocyte foot processes, controlling the passage of substances from the 
bloodstream into the  brain4,5. Besides the tight junctions that restrict the paracellular passage of drugs, brain 
endothelial cells also express a number of efflux transporters such as P-glycoprotein (P-gp) and breast cancer 
resistance protein (BCRP), thus limiting drug penetration into the  brain6. In this respect, a majority of the current 
chemotherapeutics available to treat GBM have BBB liabilities that negatively impact on therapeutic  efficacy7. 
As a result, the chemotherapeutic options are limited and those drugs that are used often require high doses that 
pose severe systemic toxicity to the normal  tissues8,9.
To address these issues, numerous engineered nanoparticles (e.g. iron oxide nanoparticles, gold nanopar-
ticles, nanoliposomes) have been used as drug delivery systems capable of penetrating the BBB and delivering 
therapeutic agents to the GBM tumor  site10. Iron oxide nanoparticles [IONPs, magnetite  (Fe3O4) or maghemite 
(γ-Fe2O3)], inter alia, have found extensive applications in cancer theranostics by virtue of their tunable size-
dependent magnetic properties. The IONPs are biocompatible and biodegradable, and can be incorporated into 
the body’s iron cycle upon  degradation5,11. Furthermore, the surface of IONPs can be further modified in order to 
(i) improve their biocompatibility and aqueous dispersibility, (ii) prolong their circulating time in blood through 
minimizing nonspecific phagocytosis by the reticuloendothelial system (RES) and also, (iii) provide active sites 
for drug  loading10,12. To this end, a variety of biopolymers such as poly(ethylene glycol) (PEG)13, poly(ethylene 
imine) (PEI)14,  dextran15 and  chitosan16 have been employed for surface modification of IONPs.
Generally, the inherent magnetic properties of the IONPs make them a promising option for both magnetic 
resonance imaging (MRI) as a contrast agent, and for site-specific magnetic targeting using an external magnetic 
 field11. Several types of IONPs have been developed as MRI contrast agents in clinical trials such as Ferumoxide 
(Feridex), Ferumoxytol (Feraheme), Ferucarbotran (Resovist) and ferumoxtran-10 (Combidex), due to their 
effective reduction of T1, T2, and T2* relaxation  times10. Moreover, several IONPs have been fabricated as an 
efficacious nanocarrier for anti-cancer drugs such as  DOX17,  paclitaxel18 and 5-fluorouracil19, albeit none of these 
have progressed to clinical trials yet.
Doxorubicin (DOX) is an anthracycline with potent antitumor activity in a variety of cancer  cells20. Gen-
erally, DOX intercalates base pairs of the DNA strands, thus inhibiting the synthesis of DNA as well as RNA 
through blocking the replication and transcription processes. In addition, DOX inhibits topoisomerase II (TOP2), 
an enzyme regulating DNA under- and over-winding, further preventing DNA replication, transcription and 
repair. Generation of free radicals is another mechanism of DOX activity that induces oxidative damage result-
ing in cleavage or degradation of  DNA20,21. DOX is considered as one of the most effective chemotherapeutics 
and is currently indicated by the FDA for a variety of neoplastic conditions such as leukemia, neuroblastoma, 
soft tissue and bone sarcoma, breast carcinoma, ovarian carcinoma, bladder carcinoma, thyroid carcinoma, 
gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic  carcinoma20. Intravenous (i.v.) 
administration of DOX, however, exhibits several adverse effects including dose-limiting cardiotoxicity and 
 myelosuppression20. The underlying mechanisms of cardiotoxicity are mainly attributed to the overproduction 
of reactive oxygen species (ROS) and inhibition of topoisomerase IIβ (Top2β)22. While DOX is a potent and 
effective chemotherapeutic in vitro against cell lines derived from malignant gliomas (IC50 of DOX is 0.5 µM 
vs temozolomide, the standard agent in glioma chemotherapy, that has an IC50 of 35 µM on U251 GBM cell 
line)23,24, its inadequate penetration across the BBB severely constrains its effective use in treating GBM patients. 
However, the therapeutic efficacy of either pegylated liposomal  DOX25 or its intratumoral  administration26 in 
patients with malignant gliomas has been reported.
Taken together, development of drug delivery systems for DOX with a capability of site-specific drug release 
and improved BBB penetration would represent a significant improvement for treatment of GBM. Thus far, 
several nanotechnology-based DOX formulations have been developed. Doxil is a pegylated liposomal formula-
tion of doxorubicin approved by the FDA for administration in a variety of human  cancers27. In addition, other 
nanotechnology-based DOX formulations such as NK-911 (DOX-conjugated poly-aspartic acid/polyethylene 
glycol micelles, phase II, metastatic pancreatic cancer) and Livatag (DOX-loaded polyalkylcyanoacrylate nano-
particles, phase III, primary liver cancer) are under clinical  trials20.
In this study, EDT-coated IONPs were developed as a delivery system for DOX and the anti-cancer effects of 
the formulation were investigated in vitro on GBM cells. EDT is a biocompatible coating that provides many neg-
ative charged sites on the surface of the  nanoparticles28,29 that can be utilized for ionic interaction with positively 
charged DOX molecules. Previous studies have demonstrated the biocompatibility of the EDT-IONPs in healthy 
Balb/c mice and the ability of transient opening of BBB to increase the brain penetration of these  nanoparticles29. 
In this study, drug-loaded EDT-IONP together with a cadherin binding peptide to transiently enhance the per-
meability of IONPs was shown to be effective in a BBB-GBM co-culture model. This combinational approach of 
using a cadherin binding peptide and an external magnetic field together not only enhanced the penetration of 
the nanoparticles but also resulted in increased therapeutic response and apoptosis in GBM cells.
Results and discussion
Characterization of EDT-IONPs. The TEM image illustrates EDT-IONPs (Fig.  1a) and DOX-EDT-
IONPs (Fig. 1b) with a quasi-spherical morphology and a core size of 4.76 ± 0.7 nm (Fig. 1c). The hydrodynamic 
diameter  (DH) and zeta potential (ζ) of the EDT-IONPs were 51.8 ± 1.3 nm, and − 27.3 ± 1.0 mV, respectively. 
The suspensions of both nanoparticles were stable at physiological pH (Fig.  1S). The FTIR spectrum of the 
EDT-IONPs is shown in Fig. 1d. The Fe–O–Fe stretching of the core was observed at 594 cm−1 and the Si–O–Si 
stretching band of the aminosilane shell was found at 991 cm−1. The carbonyl stretching band of EDT coating 
and the C-H stretching (of propyl group) bands were observed at 1,600 cm−1 and 2,927 cm−1, respectively. The 
energy-dispersive X-ray spectrum of EDT-IONPs for elemental analysis was also reported in supplementary 
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materials (Fig. 2S). The powder X-ray diffraction pattern of the nanoparticles was also shown in Fig. 3S, whose 
peaks were indexed to cubic unit cell characteristic of magnetite/maghemite  (Fe3O4/γ−Fe2O3) phase as previ-
ously reported30. The magnetic properties and additional physicochemical characterizations of the IONPs were 
previously  reported30,31.
Characterization of DOX-IONPs. The DOX loading efficiency on the EDT-IONPs was calculated to be 
5 ± 0.05%. The DOX-EDT-IONPs had a ζ of 0.0 ± 0.02 mV compared to − 20.05 ± 2.7 mV for EDT-IONPs. The 
change in surface charge of the nanoparticles upon drug loading can be attributed to the electrostatic interac-
tions between the amine groups of DOX and carboxylic acid groups of EDT coating. In addition, the  DH of 
the EDT-IONPs increased from 51.8 ± 1.3 nm (polydispersity index: PDI 0.14) to 75.5 ± 3.2 nm (PDI 0.27) 
upon DOX loading. The release profile of DOX from the nanoparticles is depicted in Fig. 1e. The nanoparticles 
demonstrated a burst release of 42 ± 5% within the initial 3 hours, while the remaining coated DOX gradually 
released within a 4-day period. Moreover, upon release of the loaded-DOX from nanoparticles within 4 days, 
the surface charge of the nanoparticles became negative again and returned to − 25.69±2.8 mV. Release studies 
performed at pH 4.5 also showed an accelerated initial release of DOX from the nanoparticles with up to 64 ± 
4% within the initial hours. The enhanced release at pH 4.5 was due to the reduced electrostatic interactions 
between DOX and  IONPs10. The increased release of DOX observed under these acidic conditions is similar to 
previous reports with DOX-IONP in the acidic tumor microenvironment or acidic cellular compartments such 
as  endosomes32,33.
The release of DOX from the IONPs observed in the present study was similar to previous reports with 
polymer-based nanoparticles. Poly-L-arginine/chitosan-coated iron oxide nanoparticles exhibited 40% and 65% 
release of DOX within 2 h at pHs 7 and 5,  respectively34. Although covalent bonding of DOX to the surface of the 
nanoparticles can result in increased loading and reduced initial burst release, these advantages are countered by 
potential reductions in the total release of the drug from the nanoparticles. For instance, when DOX was cova-
lently conjugated to iron oxide nanoparticles via a pH-sensitive hydrazone linkage, there was a 29% burst release 
within 2 h. However, only 4% of the loaded DOX was further released within 24 h and the cumulative release 
was only around 35% under acidic pH  conditions35. The release rate observed in the present study is well-suited 
for the proposed delivery approach involving transient opening of the BBB. Previous in vivo studies using the 
cadherin peptides for transient opening of the BBB indicated a therapeutic delivery window of approximately 
60 minutes following  treatment36. Thus, the DOX-EDT-IONPs would be expected to enter the brain within an 
hour, while carrying over 60% of the initial concentration of the loaded DOX. Moreover, the rapid release of DOX 
(within an hour) from the DOX-EDT-IONPs that magnetically has been drawn to the target site, can increase the 
Figure 1.  Characterization of nanoparticles: TEM images of (a) EDT-IONPs, and (b) DOX-EDT-IONPs; (c) 
histogram of EDT-IONP size distribution from the measurement of 100 particles; (d) FTIR spectrum of EDT-
IONP, (e) release of DOX from the DOX-EDT-IONPs in pH 7.4 and 4.5.
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chance of DOX entering the brain through the transiently open tight junctions of the BBB to provide a higher 
concentration of the drug within the brain.
Biocompatibility of EDT-IONPs. Biocompatibility of the EDT-IONPs on U251, bEnd.3 and MDCK-
MDR1 cells was studied. No cytotoxicity was observed in any of these three cell lines following treatment with 
EDT-IONPs at concentrations ranging from 0.25 to 30 µg/mL (Fig. 2). Furthermore, treatment of cells with 
either DOX-EDT-IONPs or free DOX (1 µg/mL) resulted in an approximately 40% reduction in the bEnd.3 cell 
viability, while no significant cytotoxicity was observed in MDCK-MDR1. This is likely attributed to the pres-
ence of P-gp efflux transporter that restricts uptake of DOX by MDCK-MDR1  cells37.
In order to deliver an effective concentration of both DOX and EDT-IONPs to GBM cells in our studies, the 
concentration of 20 µg/mL of EDT-IONPs was selected for use in the remaining studies. This concentration, 
which was well tolerated in various cell lines, enables delivering enough DOX to observe cytotoxicity on the 
tumor cells. We previously reported biocompatibility of IONPs on endothelial, astrocyte and neuron cells 
at a concentration up to 100 µg/mL38. Moreover, iron oxide nanoparticles clinically demonstrate acceptable 
biocompatibility and they are captured by the reticuloendothelial system (RES), by which the iron is incorporated 
into the body’s iron  cycle5. In practice, iron oxide nanoparticles are coated with biocompatible and hydrophilic 
materials, diminishing the non-specific protein adsorption on the nanoparticle surface and decreasing their 
recognition and clearance by the RES, thereby their circulation time, as well as accumulation in the brain tumor 
can be  augmented39.
Cellular uptake of the EDT-IONPs and DOX. The cellular uptakes of EDT-IONPs and DOX-EDT-
IONPs in bEnd.3 (Fig. 3a), MDCK-MDR1 (Fig. 3b), and U251 (Fig. 3c) were evaluated. The uptake of both 
EDT-IONP and DOX-EDT-IONP was concentration-dependent, with the drug-loaded IONPs generally dis-
playing greater cellular uptake than that of the EDT-IONPs (Fig. 3). Moreover, the cellular uptake of the nano-
particles was augmented in the presence of a magnetic field. The bEnd.3 and MDCK-MDR1 demonstrated a 
greater uptake of the nanoparticles than that of U251. While mechanistically, there are many types of endocyto-
sis pathways present in endothelial and epithelial  cells40,41, our previous studies suggest that caveolin- dependent 
endocytosis is likely the major contributor to EDT-IONPs internalization in the bEnd.3 and MDCK  cells42. The 
TEM images taken from U251 cells following EDT-IONP or DOX-EDT-IONP (Fig. 4) showing nanoparticle 
sequestration in intracellular vesicles (i.e., endosomes/lysosomes) is also supportive of an endocytosis pathway 
for uptake of the nanoparticles. Regarding the higher uptake of DOX-EDT-IONPs compared to EDT-IONPs 
observed in the MDCK-MDR1 and U251 cells, the neutral surface charge of the former would favour the cel-
lular uptake of the drug-loaded nanoparticles. Previous studies with IONPs examining the role of surface charge 
and cellular uptake have reported greater uptake of positively charged IONPs compared to negatively charged 
 IONPs38.
In terms of drug accumulation in U251 GBM cells, treatment with DOX-EDT-IONPs, was more effective than 
DOX alone. In the present study, the DOX-EDT-IONP resulted in approximately 2-fold greater uptake compared 
to an equal concentration of DOX in solution (Fig. 3d). In addition, application of an external magnetic field 
Figure 2.  Biocompatibility of EDT-IONPs on b.End3, MDCK-MDR1 and U251 cell lines after 48-h treatment 
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further enhanced the DOX accumulation in the U251 cells (2.8 ± 0.5-fold, Fig. 3c). In practice, the efficacy of 
chemotherapy with DOX is limited by the multiple drug resistance (MDR) mechanisms due to the overexpres-
sion of ATP-binding cassette (ABC) and P-gp efflux transporter in cancer cells. The expression of P-gp in U251 
has been previously  reported43. In this regard, Wang et al.,43 reported that co-administration of β-asarone and 
TMZ could decrease P-gp and MDR1 expression in U251, thus promoting TMZ’s entry into the GBM cells. 
Therefore, in this study, the DOX loaded on the nanoparticles could bypass the P-gp efflux system, leading to 
higher DOX’s uptake in the GBM  cells5,35. Similarly, higher uptake of DOX upon treatment of C6 glioma cells 
with DOX-loaded-polysorbate 80-SPIONs in comparison to that of free DOX was reported through endocytosis 
of the  nanoparticles10.
Cytotoxicity of DOX-EDT-IONPs on cancer cell. The cytotoxicity of DOX-EDT-IONPs against U251 
was studied in comparison to free DOX at different concentrations (0.25, 0.5 and 1 µg/mL). Based on the MTT 
assay, the cell viability upon a 48 h-treatment with DOX and DOX-EDT-IONPs (at concentration of 1 µg/mL 
of DOX) decreased to 25% ± 1% and more significantly to 17% ± 2% (p < 0.05), respectively, while no cyto-
Figure 3.  Uptake of EDT-IONPs and DOX-EDT-IONPs by (a) b.End 3, (b) MDCK-MDR1, and (c) U251 after 
4-h treatment. (d) Uptake of DOX by U251 cells treated with either DOX, DOX-EDT-IONPs, or DOX-EDT-
IONPs + Magnet after 2 h. *Indicates a significant difference compared to DOX at p < 0.05. Data is presented as 
mean ± S.D, and n = 3 (three replications). IONPs and DOX-IONPs represent for EDT-IONPs and DOX-EDT-
IONPs.
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toxic effects of the EDT-IONPs alone observed in the GBM cells (Fig. 5). It should be noted that the  IC50 of 
DOX was found to be ca. 300 ng/mL (Fig. 4S), and both concentrations of DOX (either free DOX or DOX-
EDT-IONPs) examined (0.5 and 1 µg/mL) were above the  IC50 value. Based on initial cytotoxic response to 
the DOX-EDT-IONPs, a 1 µg/mL DOX concentration was selected for the nanoparticle formulations in sub-
sequent studies. Compared to free DOX (1 µg/ml) there was a modest but significant increase in cytotoxicity 
with the DOX-EDT-IONP. A similar cytotoxic effect of DOX released from DOX-loaded-chitosan-modified 
 Fe3O4  nanoparticles12, and core-shell nanocarriers (ZnO-polyacrylamide-DOX)44 against GBM cell lines have 
previously been reported. In addition to the modest improvement in cytotoxicity of DOX when administered as 
DOX-EDT-IONPs on GBM cells, the capability of DOX-EDT-IONPs to improve DOX’s delivery across the bio-
logical barriers is also of importance in determining overall improvements with the IONP formulation. More-
over, the DOX-EDT-IONPs potentially provide the capability of site-specific magnetic targeting to diminish 
DOX’s systemic side  effects10,12. For example, Xu et al.,10 reported that IONPs could enhance DOX uptake by C6 
glioma cells in rats bearing intracranial tumors particularly in the presence of an external magnetic field, while 
DOX-associated toxicity was prevented. Correspondingly, animal survival was prolonged from 32 and 38.5 days 
for mice treated with DOX and DOX-IONPs, respectively to 79.2 days for mice treated with DOX-IONPs in the 
presence of an external magnetic field.
Induction of apoptosis through DNA damage via intercalation into DNA and inhibition of topoisomerase-II 
is a de facto mechanism of DOX’s  cytotoxicity45. In this study, both DOX and DOX-EDT-IONPs were found to 
be effective at inducing apoptosis in U251 cells after 72 h, leading to ca. 93% late apoptotic cell death, and no 
considerable cell viability (Fig. 6). In late apoptosis, the cellular membrane integrity is lost, thus cells demonstrate 
staining with both annexin V-FITC (+)/PI (+) 46. Likewise, treatments with both DOX and DOX-EDT-IONPs 
significantly inhibited GBM cell proliferation by over 90% (Fig. 7). Similarly, the anti-proliferative effects of DOX 
loaded in catanionic solid lipid nanoparticles (CASLNs)47 and DOX-polyglycerol-nanodiamond  composites48 
were reported on U87 GBM cell line. For example, Kuo et al.,47 reported a greater anti-proliferative effect of 
DOX-CASLNs than that of free DOX due to the higher DOX accumulation in GBM cells through a vesicular 
uptake pathway.
The studies of cell morphology indicated that in addition to a significant reduction in the cell population, both 
DOX and DOX-EDT-IONPs treatments induced notable morphological changes from a cuboidal morphology of 
normal U251 to a shrunken and spindle-like structure of actin cytoskeleton and a disrupted nucleus (Fig. 8). The 
effect of DOX in induction of remodeling in actin cytoskeleton and disruption of central stress fibers leading to 
impaired cell adhesion and increased cell detachment has been reported  previously49. Moreover, phosphorylated 
H2AX (γ-H2AX), mediating DNA double-strand break, is an early and sensitive biomarker in DNA double‐
strand break  response50. In Fig. 8, γ-H2AX can be visualized as foci by immunofluorescence in U251 treated 
with either DOX or DOX-EDT-IONPs. Such findings indicate DNA damage following DOX treatment in GBM 
cells. This is in accordance with previous findings of DOX-induced DNA damage and appearance of γ-H2AX 
in  breast50 and  lung51 cancer cells. It is noteworthy to mention that iron oxide nanoparticles typically show 
quenching effect of DOX fluorescence  intensity52 and as a result the DOX-EDT-IONPs could not be observed 
inside the cells by fluorescence microscopy.
The studies of cell morphology indicated that in addition to a significant reduction in the cell population, both 
DOX and DOX-EDT-IONPs treatments induced notable morphological changes from a cuboidal morphology of 
normal U251 to a shrunken and spindle-like structure of actin cytoskeleton and a disrupted nucleus (Fig. 8). The 
effect of DOX in induction of remodeling in actin cytoskeleton and disruption of central stress fibers leading to 
impaired cell adhesion and increased cell detachment has been reported  previously49. Moreover, phosphorylated 
H2AX (γ-H2AX), mediating DNA double-strand break, is an early and sensitive biomarker in DNA double‐
strand break  response50. In Fig. 8, γ-H2AX can be visualized as foci by immunofluorescence in U251 treated 
with either DOX or DOX-EDT-IONPs. Such findings indicate DNA damage following DOX treatment in GBM 
cells. This is in accordance with previous findings of DOX-induced DNA damage and appearance of γ-H2AX 
in  breast50 and  lung51 cancer cells.
Figure 5.  Cytotoxicity assessment of various concentrations of DOX and DOX-EDT-IONPs (0.25, 0.5 and 
0.1 µg/mL) on U251 after 48 h treatment. *Indicates a significant difference at p < 0.05. Data is presented as 
mean ± S.D, and n = 6. The Y-axis represents cell viability compared to the control. IONPs and DOX-IONPs 
represent for EDT-IONPs and DOX-EDT-IONPs.
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ROS generation. ROS generation is a well-known mechanism involved in DOX-induced apoptotic death 
in various cancer cells such as human osteosarcoma Saos-253, and human ovarian cancer  cells54. In the present 
study, treatment of U251 with either DOX or DOX-EDT-IONPs increased the formation of ROS by 1.9 ± 0.1 
and 2.2 ± 0.2 fold, respectively within 72 h, while only DOX-EDT-IONPs showed a ROS-inducing effect at 48 h 
(Fig. 9). Similarly, the effect of DOX on ROS induction and apoptosis in U87 GBM cell line has been  reported55. 
It is also noteworthy to mention that ROS-induction is one of cytotoxicites associated with bare IONPs and over 
800% enhancement in the intracellular ROS was reported into porcine endothelial cells (3 h exposure, 0.5 mg/
mL of IONPs)56. Nonetheless, our findings indicated that the synthesized EDT-IONPs were biocompatible and 
did not induce intracellular ROS per se. Taken together, triggered ROS-mediated DNA damage is suggested as 
one of the potential mechanisms of DOX-induced cell apoptosis in human GBM cells.
Quantitative RT-PCR. To demonstrate the anti-cancer effect and mechanism of DOX and DOX-EDT-
IONPs treatments on U251, a series of gene studies was conducted (Fig. 10). Topoisomerase IIα (Top II) is a key 
enzyme in DNA replication, which is considered as a prominent molecular target of several anti-cancer drugs 
such as DOX and  etoposide57. DOX inhibits topoisomerase II (TOP2), by which the DNA replication, transcrip-
tion and repair are  interrupted21. Ku70, a DNA-dependent protein kinase, is another factor involved in the repair 
of DNA double-strand breaks and known as a survival factor in some cancer  cells58. Treatment of U251 with 
DOX-EDT-IONPs reduced markedly the expression of both Ku70 and Top II, which would further reduce DNA 
repair and replication in the GBM cells.
Caspases are essential mediators of programmed cell death and they are triggered sequentially, in which 
activation of Caspase 12 leads to the activation of Caspase 9 and the subsequent ‘effector’ Caspase  359. Both 
DOX and DOX-EDT-IONPs treatments upregulated the Caspase 3 gene expression, which is consistent with 
Figure 6.  Flow cytometer analysis for cell apoptosis/necrosis of U251 upon 48-h treatment, stained with 
Annexin V-FITC and PI. (a) Control, (b) EDT-IONPs, (c) DOX, and (d) DOX-EDT-IONPs. (Q4) demonstrates 
Live, (Q3) early apoptotic, (Q2) late apoptotic and (Q1) necrotic cells.
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its upregulation in C6  glioma10, leukemia HL-6060, and MCF-7 breast  cancer61 cells upon DOX treatments. 
p53 is a tumor suppressor protein whose mutation is the most prevalent genetic alteration in human  cancers62. 
In fact, the p53 protein can inhibit DNA synthesis and regulates cell apoptosis through competition with the 
Figure 7.  Flow cytometer analysis for cell proliferation assay of carboxyfluorescein succinimidyl ester (CFSE)-
labelled U251 upon treatment with EDT-IONPs, DOX and DOX-EDT-IONPs. (a) CFSE flow cytometry graph, 
and (b) the relative cell proliferation inhibition calculated by (mean CFSE control/mean CFSE treated). *Shows 
a significant difference compared to the control group at p < 0.05. IONPs and DOX-IONPs represent for EDT-
IONPs and DOX-EDT-IONPs.
Figure 8.  Fluorescence microscopy images of U251 with or without treatment after 48 h. Red, blue and green 
fluorescence colours represent Alexa Fluor@ 488 phalloidin-stained F-actin, DAPI-stained cell nuclei, and 
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DNA repair  mechanisms21. The U251 cells treated with DOX and DOX-EDT-IONPs exhibited an upregulated 
expression of p53.
Maternally Expressed Gene 3 (MEG3) is an imprinted non-coding RNA that acts as a tumor suppressor 
through both p53-dependent and p53-independent  pathways63. Furthermore, it has been found that MEG3 
expression markedly is diminished in glioma tumors, whereas whose expression can inhibit cell proliferation and 
promoted cell apoptosis in U251 and U87 GBM cell  lines64. lncRNA-growth arrest-specific 5 (Gas5) is another 
tumor-suppressor gene that is downregulated in glioma  cells65. Suppressing the GBM tumor malignancy has been 
observed through introduction of Gas 5 and consequently downregulation of miR-22266. Here, both DOX and 
DOX-EDT-IONPs treatments were found to be effective in upregulation of both tumor suppressors, i.e. MEG3 
and Gas5, which potentially leads to GBM cell apoptosis.
MiR-155 is an important oncogenic microRNA that is overexpressed in various malignant tumors including 
GBM, whose mechanism of action is associated with a blockade of Caspase-3 activity and regulation of 
multiple genes involved in cancer cell proliferation, and  invasiveness67. The expression of MiR-155 in U251 
was downregulated upon treatment with either DOX (0.457 ± 0.24 fold) or more significantly with DOX-EDT-
IONPs (0.28 ± 0.03-fold, p < 0.05). It also has been reported that downregulation of MiR-155 can enhance the 
chemosensitivity of U251 cells to Taxol by interrupting the activity of EAG1 pathways and inducing  apoptosis67.
In addition, the Wnt signaling pathway plays an important role in malignant transformation and tumor 
progression in  gliomas68, and the capacity of intracranial tumor formation has been found to be reduced upon 
Wnt silencing, in vivo69. Here, U251 demonstrated a significant downregulation of Wnt1 upon the treatments 
with either DOX (0.21 ± 0.04 fold) or DOX-EDT-IONPs (0.17 ± 0.03 fold).
Figure 9.  ROS induction by EDT-IONPs, DOX or DOX-EDT-IONPs in U251 at different time-points. 
*Indicates a significant difference compared to the control group at p < 0.05. Data is presented as mean ± S.D, 
and n = 5. IONPs and DOX-IONPs represent for EDT-IONPs and DOX-EDT-IONPs.
Figure 10.  Relative gene expression of U251 cell upon treatment with either EDT-IONPs, DOX or DOX-
EDT-IONPs for 48 h. *Indicates a significant difference compared to the control group, and **compared to 
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Anti-cancer effect of DOX-EDT-IONPs (in vitro GBM model). Due to the inability of DOX to cross 
the BBB and penetrate into the tumor site, it demonstrates little effectiveness in treating GBM when adminis-
tered  systemically70. Having considered that, development of an efficient drug delivery system enabling pen-
etration of DOX across the BBB and enhancing its bioavailability is a matter of significant importance in GBM 
chemotherapy. In selecting the most appropriate cell culture model of the BBB to evaluate the DOX-EDT-IONP 
delivery approach, both the bEnd.3 brain endothelial cell line and the MDCK-MDR1 cell line were considered. 
Our previous studies with bEnd.3 indicated this particular model was well suited for examining nanoparticle 
 permeability71. However, the available brain endothelial cell culture models do not form a restrictive paracellular 
barrier required for screening the passage of small  molecules72 and because of this often overestimate the BBB 
penetration. The MDCK-MDR1 cells overexpress P-gp and have reduced paracellular diffusion of solutes due to 
the complex tight junction proteins. For this reason, the MDCK-MDR1 cell line is often used to assess the BBB 
permeability and P-gp liabilities of drugs for central nervous system  indications73. Since the penetration of DOX 
across the BBB is mainly restricted by the P-gp expression under normal physiological  conditions74, the MDCK-
MDR1 cells overexpressing P-gp were used in the present study to provide a more representative barrier cell for 
the BBB-GBM co-culture model.
The limited penetration of DOX was apparent in the BBB-GBM co-culture model (Fig. 11a). The DOX 
permeability across the MDCK-MDR1 monolayers reached approximately 18% after 4 hours. The DOX that 
penetrated the MDCK-MDR1 monolayers had reduced cytotoxicity compared to that observed with 1 μg/ml of 
DOX in U251 monocultures. The DOX-EDT-IONP formulation showed a significant increase (ca. 1.5-fold) in 
penetration of DOX compared to DOX alone in the BBB-GBM co-culture model (Fig. 11a). As DOX is a sub-
strate of P-gp efflux transporter that highly restricts its penetration into the  brain74, the improvement in DOX 
permeability observed in the present study is attributed to the DOX-loaded nanoparticles circumventing the 
P-gp efflux transporter in the MDCK-MDR1 monolayers. However, despite the increase in permeability observed 
with DOX-EDT-IONP in the in vitro BBB-GBM co-culture model, the resulting cytotoxicity in U251 was not 
significantly greater than that of DOX alone (Fig. 11b). This suggests that improvement in DOX permeability 
with the IONP formulation alone was not sufficient to produce an enhanced cytotoxic response and additional 
measures were necessary to impact both permeability and response in the BBB-GBM co-culture model.
Transient disruption of the BBB with hyperosmotic solutions like mannitol has been reported to enhance the 
delivery of therapeutic molecules as well as IONPs into the  brain75,76. In this regard, mannitol has extensively 
been used in combination with anti-tumor agents in clinical trials of glioma therapy over the last three  decades77. 
Similarly, Sun et al.,78 reported a significant increase in permeability of both EDT-IONPs and aminosilane-coated 
(AmS)-IONPs across brain endothelial cell monolayers when tight junctions were disrupted using mannitol. 
However, the extensive opening of the BBB by mannitol and the long recovery time for re-establishment of the 
BBB integrity can cause a substantial and uncontrolled influx of low and high molecular weight substances 
from the blood into the brain that can result in neurological toxicity, jeopardizing patient  safety79. Previous 
studies using cadherin binding peptides to modulate BBB permeability suggested a more controlled opening of 
the BBB in terms of both magnitude and duration of opening was  possible80. In the present study, the cadherin 
binding peptide, ADTC5 was used to transiently modulate permeability in the BBB-GBM co-culture model. 
While ADTC5 was able to increase the permeability of the DOX-ECT-IONPs, especially when combined with 
an external magnetic field (Fig. 11), wholesale disruption of monolayer integrity was much less than observed 
with hyperosmotic mannitol, as demonstrated by the permeability to the 35 kDa molecular weight IRDye [2.7 ± 
0.4% and 3.1 ± 0.3% without and with ADTC5, respectively, compared to 15.6 ± 0.6% with mannitol (Fig. 5S)]. 
Moreover, as mentioned previously, the recovery time for re-establishment of the BBB integrity was reported to 
be within 60 min post-injection of the cadherin binding peptide in vivo36. This means that using the cadherin 
peptide allowed the MDCK-MDR1 monolayers to maintain barrier properties to large IRDye macromolecule 
marker, while allowing enhanced penetration to the IONPs, especially in the presence of an external magnetic 
field. We have named this approach magnetic enhanced convective diffusion (MECD) as the IONPs diffuse across 
the transiently disrupted cell barrier in a bulk flow manner that is accelerated by the presence of an external 
magnetic field.
By transiently opening the MDCK-MDR1 monolayer tight junctions using ADTC5 and in combination with 
an external magnetic field, the GBM cell viability significantly decreased upon treatment with DOX-EDT-IONPs 
compared to the GBM cells treated with free DOX (cell viability 66 ± 3.3% and 45 ± 3.7% for GBM cells treated 
with free DOX and DOX-EDT-IONPs, respectively) (Fig. 11b). This result was consistent with the higher DOX-
EDT-IONP permeability through the MDCK-MDR1 monolayer when both ADTC5 and external magnetic 
fields were applied.
The permeability of DOX-EDT-IONPs through BBB-GBM co-culture model was also examined. Under 
normal conditions, DOX-EDT-IONPs showed 5.2 ± 0.4% penetration across the MDCK-MDR1 monolayer over 4 
hours. The diffusion of DOX-EDT-IONPs could be increased by either enhancing the MDCK-MDR1 monolayer 
permeability with ADTC5 (6.2 ± 0.45%) or by application of an external magnetic field (7.4 ± 0.5%) (Fig. 11c). 
However, combining both ADTC5 treatment with an external magnetic field significantly augment DOX-EDT-
IONP penetration by 8.5 ± 0.36%. To the best of our knowledge, this is the first report on the combinational effect 
of cadherin binding peptide and external magnetic field as an effective approach to enhance the permeability of 
drug delivery systems across the BBB.
As mentioned earlier, IONPs uniquely provide a site-specific magnetic targeting utilizing an external mag-
netic field to draw the nanoparticles to the site of action and enhancing their  bioavailability81. For instance, by 
applying an external magnetic field, overall tumor exposure to magnetic nanoparticles was enhanced by 5-fold 
compared to non-targeted  tumors82. Moreover, ADTC5 has shown an enhanced delivery of various marker 
molecules (e.g., 14C -mannitol, Gd-DTPA) across the MDCK monolayer in vitro, and the BBB in vivo through 
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Figure 11.  Anti-cancer efficacy of DOX-EDT-IONPs compared to the free DOX on an MDCK-MDR-GBM model in vitro. 
(a) DOX permeability across the MDCK-MDR1 monolayer with or without IONPs in the presence or absence of magnet and 
ADTC5 (b) cytotoxicity of each formulation on U251 cells after penetrating the monolayer. (c) DOX-IONPs permeability 
across the MDCK-MDR1 monolayer with or without magnet and ADTC5. *Indicates a significant difference at p < 0.05 with 
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binding to the EC1 domain of E-cadherin, blocking the cadherin–cadherin interactions and thus enhancing the 
delivery of molecules into the brain via the paracellular pathway of the  BBB80.
Therefore, the developed DOX-EDT-IONPs in combination with the magnetic enhanced convective diffusion 
and the cadherin binding peptide for transiently opening the BBB tight junctions were found effective to enhance 
DOX’s bioavailability and anti-cancer effect in GBM cells by virtue of overcoming the MDR and enhancing the 
permeability of DOX through a BBB model in vitro.
This combinational approach can potentially be an efficacious alternative for the passive targeting through 
the enhanced permeability and retention (EPR) effect, or ligand-based active targeting of the IONPs in clinical 
practice. In fact, the EPR effect in humans has been found not as prominent as in animal  models83. Moreover, 
during early stages of brain tumor development, the EPR effect cannot play an important role inasmuch as the 
BBB is still intact, and leakiness is observed at the stages when tumor volume is high and difficult to  treat84. 
In addition, the infiltrating tumor cells are mostly associated with the intact BBB that would impede passive 
targeting of  nanoparticles85. On the other hand, the clinical outcomes of active targeting of nanoparticles to brain 
tumors have not yielded the results anticipated due to altered expression of target receptors in some types of 
tumors, tumor heterogeneity and the interpatient  variability86. BIND-014 and MM-302 are two examples of active 
targeting nanomedicines that failed in clinical  studies87. In light of these clinical studies, this novel combinational 
approach of using cadherin binding peptide for transiently opening the BBB tight junctions in juxtaposition with 
magnetic enhanced convective diffusion can be an alternative and effective approach for the passive targeting 
and ligand-based active targeting of drug-loaded IONPs in clinical practice. This combinational approach can 
provide a site-specific magnetic targeting to reduce systemic distribution of the drug-loaded IONPs, a transiently 
opening of the BBB tight junctions using a cadherin binding peptide, and an enhanced convective diffusion of 
the magnetic nanoparticles into the brain. These together can reduce the systemic toxicity of chemotherapy, 
enhance the permeability of the drug-loaded nanoparticles into the brain and ameliorate the efficacy of GBM 
chemotherapy by providing a therapeutic concentration of the effective anti-cancer drugs like DOX that are 
intrinsically impermeable to the BBB.
conclusion
In this study, DOX-EDT-IONPs were developed to facilitate drug delivery to GBM tumor cells. The DOX was 
entirely released from the DOX-EDT-IONPs within 4 days, while the nanoparticles could augment the DOX’s 
uptake in U251 cells by 2.8-fold. The DOX-EDT-IONPs was found to be effective in apoptosis-induced cell 
death, proliferation inhibition, and ROS-induction in U251 cells. Moreover, DOX-EDT-IONPs treatment could 
downregulate TOP II and Ku70, essential enzymes for DNA repair and replication, as well as MiR-155 oncogene, 
while concomitantly upregulated Caspase 3, a key mediator of apoptosis, and tumor suppressors i.e., p53, MEG3 
and GAS5, in U251 cells. Furthermore, recruiting an in vitro MDCK-MDR-GBM co-culture model, the EDT-
IONPs could enhance DOX penetration through the MDCK-MDR1 monolayer over twofold and provided 
significantly higher anti-cancer effect than free DOX in GBM cells in the presence of an external magnetic field 
and ADTC5. In addition, the DOX-EDT-IONPs showed increased permeability through the MDCK-MDR1 
monolayer that was further significantly increased in the presence of an external magnetic field. The results of 
these studies suggest magnetically driven enhanced diffusion of DOX-EDT-IONPs across the MDCK-MDR1 
monolayer. However, the largest increase in DOX-EDT-IONP permeability in the BBB-GBM co-culture model 
was observed using a cyclic ADT peptide as a transient disruption agent in combination with an external 
magnetic field. The combination of an external magnetic field and a cadherin binding peptide augmented the 
penetration of the DOX-EDT-IONPs, under conditions that did not extensively disrupt the BBB as compared 
to other techniques like hyperosmotic treatment. If similar effects are observed in vivo, the advantage of this 
approach would be that the BBB remains relatively intact to large macromolecules, which correspondingly should 
diminish the risk of neurological toxicity. In conclusion, the developed DOX-EDT-IONPs in combination with 
the magnetic enhanced convective diffusion and the ADTC5 for transiently opening the BBB tight junctions 
can potentially provide an efficacious formulation of DOX in GBM chemotherapy by virtue of enhancing DOX’s 
penetration into the brain, overcoming the MDR cancer cells, providing a site-specific magnetic targeting and 
diminishing the systemic toxicity.
Materials and methods
Materials. The chemical reagents were acquired from Sigma Aldrich (St. Louis, MO), and the cell culture 
and biochemical reagents were purchased from Thermo Fisher Scientific Inc, USA, unless otherwise specified.
Synthesis and characterization of EDT-IONPs. Iron oxide nanoparticles were fabricated under mild 
conditions at room temperature as previously  described31. Briefly, Fe(acac)3 (2.83 g, 8 mmol) was dissolved in 
ethanol/DI water (6:4) and purged with nitrogen for 1 h, followed by adding  NaBH4 (3.03 g, 80.0 mmol) in 
deoxygenated DI water under stirring (1000 rpm). When the color of the reaction mixture changed from red 
to black, it indicates the formation of IONPs (approximately 20 min). For coating, (Trimethoxysilylpropyl)-
ethylenediamine triacetic acid (EDT, 16 ml) was added, and the reaction mixture was stirred overnight at room 
temperature. The blackish brown solution was filtered, and the solvent was evaporated at 50 °C under low pres-
sure. The obtained viscous mixture was dissolved in 200 ml of cold ethanol and left until excess  NaBH4 became 
crystallized, which was removed by filtration. Finally, ethanol was completely removed, the product was dis-
solved in 50 ml DI water and dialyzed against DI water to remove the unreacted EDT, followed by centrifugation 
at 4000 rpm for 30  min31. The dark reddish-brown supernatant was collected and stored for further use.
The size distribution of EDT-IONP in DI water was measured by dynamic light scattering (DLS) using a 
Photocor Complex system. The FTIR spectrum was taken using a Thermo Nicolet iS10 FTIR spectrometer. 
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Transmission electron microscopy (TEM) images of the EDT-IONPs were obtained using a Philips CM 10 
electron microscope (FEI, Hillsboro, USA).
Drug loading on EDT-IONPs. To load DOX on the EDT-IONPs, EDT-IONPs (20 µg) and DOX (20 µg) 
in 200 µL phosphate-buffered saline (PBS, pH 6) was combined and incubated overnight under ambient condi-
tions. Afterwards, the mixture was centrifuged at 12,000 rpm for 10 min and the solution was completely with-
drawn. Then, the nanoparticles were washed with PBS (pH 7.4) twice to remove free DOX and the nanoparticles 
were centrifuged again to collect the DOX-loaded EDT-IONPs (DOX-EDT-IONPs).
Biocompatibility assessment of EDT-IONPs. To assess the biocompatibility of the synthesized EDT-
IONPs, a mouse brain-derived microvessel endothelial cell line, bEnd.3 (American type tissue culture collection, 
Manassas, VA) was employed as a cell culture model for the BBB. The Madin–Darby canine kidney (MDCK) 
transfected with multi-drug resistant protein 1  (MDR) was also used. MDCK is an epithelial cell line origi-
nally derived from the normal dog kidney and transfected with MDR, expressing P-gp and tight junction pro-
teins. Therefore, the MDCK-MDR1 has been reported as a model for the BBB  permeability73. Furthermore, an 
authenticated human U251 GBM cell line was used for biocompatibility evaluation of EDT-IONPs. The bEnd.3, 
MDCK-MDR1 and U251 cells (cells at passage number 20–30) were cultured at a density of 2 × 104 (bEnd.3, 
MDCK-MDR) and 1 × 104 (U251) cell/cm2 in 96-well plates, and incubated overnight at 37 °C allowing the cells 
to attach. Next day, the cells were treated with EDT-IONPs (0.25 to 50 µg/mL) suspended in the cell culture 
medium for 48 h. Thereafter, the culture medium was removed, and the cells were washed with PBS followed 
by incubation with fresh medium containing 0.5 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-
umbromide (MTT, 0.5 mg/mL) reagent at 37 °C. After 3 h, the medium was withdrawn, and blue crystals were 
dissolved in pure  DMSO88–90. The absorbance of the solutions was measured using a Synergy HT plate reader 
(BioTek, Winooski, VT) at the wavelength of 570 nm and the relative cell viability was calculated as  [OD]test/
[OD]control, upon five measurements.
Drug release from EDT-IONPs. The release of DOX from the EDT-IONPs was measured in PBS (pH 7.4 
mimicking physiological pH, and 4.5 mimicking pH of acidic intracellular compartments such as endosomes) at 
37 °C. For this purpose, the DOX-EDT-IONPs were suspended in 1 mL PBS in Eppendorf tubes and at various 
time points, the tubes were centrifuged at 12,000 rpm for 10 min to pellet the nanoparticles and the solution was 
completely collected followed by re-suspension of the nanoparticles in 1 mL of fresh PBS. The concentration of 
the released DOX in the solution was determined by fluorescence measurement (excitation and emission wave-
lengths of 485 nm and 590 nm, respectively) using a Synergy HT plate reader. The concentration of the released 
DOX from DOX-EDT-IONPs was calculated using a serial dilution of a DOX standard solution.
Cellular uptake of EDT-IONPs and DOX. To study the cellular uptake of DOX-EDT-IONPs; bEnd.3, 
MDCK-MDR, and U251 cells were grown in 24-well culture plates to reach a confluent monolayer and then they 
were treated with cell culture medium containing either EDT-IONPs or DOX-EDT-IONPs (10 and 20 µg/mL) 
for 4 h at 37 °C with and without a static magnetic field (rare-earth circular magnets, diameter: 20 mm, Lee Val-
ley, Winnipeg, CA). Then the cells were washed with cold PBS to remove non-adhered nanoparticles, and lysed 
with 0.1% triton solution in PBS overnight at − 20 °C. The content of IONPs was determined based upon the 
Ferrozine assay as previously  reported38. Briefly, HCl (500 µL of 12 M) was added to wells, and were incubated at 
room temperature for 1 h with gentle shaking to digest the IONPs, followed by neutralization with NaOH (500 
µL of 12 M). Then, hydroxylamine hydrochloride (120 µL of 2.8 M) in 4 M HCl was added, and the samples were 
incubated for 1 h at room temperature with gentle shaking. Afterwards, ammonium acetate solution (50 µL of 
10 M, pH 9.5) and ferrozine (300 µL of 10 mM) in 0.1 M ammonium acetate solution were added sequentially 
to each well, and the absorbance of the solutions was determined at 562 nm by a Synergy HT plate reader. The 
concentration of EDT-IONPs was quantified based upon an iron chloride standard solution. The protein content 
of the lysed cells was also measured using a BCA protein assay kit.
The localization of EDT-IONPs in the cell organelles was also studied using TEM as previously  described29,42. 
For this purpose, U251 cells were treated with either EDT-IONPs or DOX-EDT-IONPs in accordance with the 
uptake study, and after washing with PBS, the cells were disassociated using a 0.25% trypsin EDTA solution 
(Hyclone, Logan, UT). After centrifugation of the collected cells (5 mins at 1500 g), the cell pellet was resuspended 
in 3% glutaraldehyde in 0.1 M phosphate buffer (pH 7.3) for 3 hours at room temperature. Then the samples were 
fixed for 2 h at room temperature in 1% osmium tetroxide in 0.1 M phosphate buffer, dehydrated in ascending 
concentrations of ethanol and embedded in Epon resin. Thin sections were stained with uranyl acetate and lead 
citrate, and photographed by TEM.
To measure the cellular uptake of DOX, U251 cells were grown in 6-well plates as described earlier and treated 
with cell culture media supplemented with an equal drug concentration of either DOX or DOX-EDT-IONPs 
to initiate the cellular drug accumulation. After 2 h, the cells were washed with cold PBS three times and lysed 
with 0.1% triton solution in PBS as described somewhere  else91. The concentration of DOX in the cell lysates was 
measured as delineated in section “Drug release from EDT-IONPs” and normalized with the protein content 
of the lysed cells.
Cytotoxicity of DOX-EDT-IONPs in GB cell line. The cytotoxicity of DOX-EDT-IONPs against U251 
cells was studied using MTT and flow cytometry analyses. For MTT assay, the cells were cultured as described 
in section “Cytotoxicity of DOX-EDT-IONPs on cancer cell”. Next day, the medium was changed with fresh 
medium (negative control), medium containing free DOX with equivalent concentrations corresponding to 
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DOX released from EDT-IONPs at the same period of time (positive control), EDT-IONPs and DOX-EDT-
IONPs. After a 48-h treatment, viability of the cells was determined by MTT assay as described in section “Bio-
compatibility assessment of EDT-IONPs”.
Moreover, cell apoptosis/necrosis was investigated using Annexin V-FITC/PI apoptosis Kit. For this study, 
the cells were treated with either EDT-IONPs, free DOX or DOX-EDT-IONPs over a 48-h period, followed by 
incubation in fresh cell culture media without any treatment for 24 h. Afterwards, the cells were stained with 
Annexin V-FITC and PI in accordance with the manufacturer’s protocol, and consequently were analyzed using 
flow cytometry (BD FACSCanto II Flow Cytometer instrument (BD Bioscience)). In addition, to study the 
effect of various treatments on cell proliferation, U251 cells were stained with a fluorescent carboxyfluorescein 
succinimidyl ester dye (CFSE, 50 mM), for 20 min at 37 °C. Thereafter, the medium was removed, and the cells 
were washed and treated with either free DOX, EDT-IONPs, or DOX-EDT-IONPs for 48 h followed by changing 
the media and leaving the cells without further treatment for 24 h. Then, the fluorescence intensity of the cells 
was determined using flow cytometry. In fact, during each cell division, the cellular content of CFSE decreases 
that results in a sequential halving of the cellular fluorescent intensity with each mitotic  event92.
To observe any changes in morphology, the U251 cells were treated for 48 h as mentioned above, followed by 
washing with PBS, fixating with paraformaldehyde (4% v/v) for 20 min at room temperature and permeabilization 
with Triton X-100 (0.2% v/v) for 10 min. The specimens were then blocked with BSA solution (3% w/v) for 1 h 
at room temperature, washed with PBS, and the cells incubated with primary phosho-H2AX antibody solution 
(1:500 in 3% BSA, 0.3% Triton X-100 in PBS) at 4°C overnight. Afterwards, the primary antibody was withdrawn, 
and a goat anti-rabbit secondary antibody labeled with Alexa 488 dye (1:500 in the same buffer as the primary 
antibody) was added to each well and incubated at room temperature for 1 h. Then, the cells were washed with 
PBS and the actin cytoskeleton was stained with ActinRed for 30 min followed by the nucleus staining with DAPI 
solution (100 nM) for 5 min at 37 °C. Finally, the samples were washed with PBS and visualized by a fluorescence 
microscope (Zeiss Axio observer Z1, Germany).
Reactive oxygen species measurement. The extent to which the various treatments resulted in 
ROS generation in the U251 cells was evaluated via the peroxide-dependent oxidation of the non-fluorescent 
2′,7′-dichlorofuorescein diacetate (DCFDA). In this cell-based assay, DCFDA freely diffuses into the cells. Once 
inside, the DCFDA is transformed to the highly fluorescent and cell impermeable 2′,7′-dichlorofluorescein 
(DCF) through ROS mediated  metabolism93. For this study, the cells were cultured in black 96 well plates at a 
density of 5000 cell/cm2. Next day, the cells were washed with PBS and exposed to 50 μM DCFHDA in PBS for 
45 min at 37 °C. Afterwards, the DCFHDA solution was removed, and the cells were washed and treated with 
either EDT-IONPs, DOX or DOX-EDT-IONPs in cell culture media over 72 h. At various time points, cellular 
accumulation of ROS in response to the treatments was calculated by measuring the oxidation of DCFDA to the 
fluorescent DCF using a Synergy HT fluorescent plate reader at Ex/Em 485/590 nm.
Quantitative RT-PCR. The gene studies were conducted on U251 cells upon a 48-h treatment with either 
EDT-IONPs, DOX or DOX-EDT-IONPs. To this end, total RNA of the cells was extracted using TRIZOL reagent 
(Invitrogen, USA) according to the manufacturer’s protocol. Then, the purity and concentration of the extracted 
RNA were determined by UV-VIS spectrophotometry (NanoDrop, Thermo Fisher Scientific Inc, USA). After-
wards, the level of mRNA encoding Top II, Ku70, p53, Caspase 3, Wnt 1, MEG3, GAS5, and MIR155 was deter-
mined by quantitative reverse-transcript polymerase chain reaction (qRT-PCR). The RT-PCR was implemented 
using iTaq Universal SYBR Green Supermix kit (Bio-Rad, USA) in an Applied Biosystems 7300 Real-Time PCR 
system and β-actin was employed as the housekeeping gene. The following thermal cycles were designed for the 
reactions: 1 cycle of 10 min at 50 °C for the reverse transcription reaction, 1 cycle of 1 min at 95 °C for polymerase 
activation, 40 cycles consisting of 15 s at 95 °C for denaturation and 1 min at 60 °C for annealing. The expression 
of the target genes was normalized to the β-actin expression and relative gene fold changes were calculated using 
the comparative  Ct method  (2−ΔΔCt) as mentioned  previously88. The primer sequences are shown in Table 1.
In vitro BBB-GBM model. Nanoparticles as a drug carrier for brain tumor therapy need to first over-
come the limited permeability of the BBB as well as the efflux transporters such as P-gp expressed on the brain 
endothelial cells, which are responsible for low drug permeation into the brain. The Madin–Darby canine kidney 
epithelial cell line stably transfected with human multi-drug resistant protein 1 (MDCK-MDR) cells overex-
press P-gp, and have reduced paracellular diffusion due to the complex tight junction proteins. Together these 
properties make MDCK-MDR1 cells a reproducible and accurate in vitro cell culture model for examining and 
predicting the penetration of drugs and solutes across the  BBB73. In the present study, MDCK-MDR1 cells (pas-
sage number 20–30, cell density 100,000 cell/cm2 were plated on the apical side of a porous polycarbonate mem-
brane inserts (4.6  cm2 pore size: 3.0 μm, Corning Inc., USA). Once a confluent MDCK-MDR1 monolayer was 
obtained (typically in 6 days), U251 cells were cultured in the basolateral side of the well plates. Free DOX (1 µg/
mL) or DOX-EDT-IONPs was added to the apical media compartment of the insert along with an IRdye 800CW 
PEG as a permeability marker. In addition, a cyclic ADTC5 peptide (Cyclo(1,7)Ac-CDTPPVC-NH2), which 
was synthesized as previously  reported94 was added to the apical media compartment of the insert to block the 
cadherin–cadherin interactions and thus enhancing drug delivery through the MDCK-MDR1 monolayer. The 
cells were then incubated at 37 °C for 4 h in both the presence and absence of a static magnetic field (rare-earth 
circular magnet, diameter: 30 mm, Lee Valley, Winnipeg, CA). Afterwards, the apical media and the inserts were 
removed and the GBM cells with the basolateral cell culture media were incubated for an additional 48-h after 
which the basolateral media was collected to determine IONP (Ferrozine assay) and IR dye permeability as well 
as the cell viability (MTT assay).
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Statistical analysis. The studies were conducted in triplicate and the results were reported as the 
mean ± standard deviation (SD). Statistical analysis was conducted using analysis of variance (ANOVA) and 
p < 0.05 was considered as the criterion of significance, as previously reported.
Data availability
The datasets produced during and/or analysed during the current study can be available from the corresponding 
author on reasonable requests.
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